Back
Open Access

Do we need routine CYP2C19 testing to improve Mavacamten safety?

Session: CYP2C19 testing uses in Cardiovascular medicine to optimize benefit/risk profile of multiple therapeutics
Topic: Pharmacology and Pharmacotherapy
Event: EuroCVP 2024 – The Annual meeting on advances in cardiovascular pharmacotherapy

Seminar Presentation

Add to my library

Like

2 more presentations in this session

CYP2C19 testing to optimize antiplatelet choice after PCI

Access
Slides
Like
Thumbnail

The European and UK regulatory advice and process CYP guided prescribing for Mavacamten and Clopidogrel

Access
Slides
Like
Thumbnail

Access the full session

CYP2C19 testing uses in Cardiovascular medicine to optimize benefit/risk profile of multiple therapeutics

Access
Like
Thumbnail

About the event

Image

EuroCVP 2024 – The Annual meeting on advances in cardiovascular pharmacotherapy

7 November - 9 November 2024

Seminar
logo Image
Access

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources